Jump Financial LLC Lowers Position in Quest Diagnostics Incorporated (NYSE:DGX)

Jump Financial LLC trimmed its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 51.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,500 shares of the medical research company's stock after selling 2,661 shares during the quarter. Jump Financial LLC's holdings in Quest Diagnostics were worth $377,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DGX. Barclays PLC boosted its position in shares of Quest Diagnostics by 35.9% during the 3rd quarter. Barclays PLC now owns 298,922 shares of the medical research company's stock worth $46,407,000 after purchasing an additional 78,980 shares in the last quarter. Te Ahumairangi Investment Management Ltd lifted its stake in shares of Quest Diagnostics by 3.1% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,004 shares of the medical research company's stock valued at $7,719,000 after buying an additional 1,520 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its holdings in Quest Diagnostics by 13.1% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 34,708 shares of the medical research company's stock worth $5,388,000 after purchasing an additional 4,024 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Quest Diagnostics during the third quarter valued at approximately $201,000. Finally, Franklin Resources Inc. boosted its stake in Quest Diagnostics by 45.8% during the third quarter. Franklin Resources Inc. now owns 54,897 shares of the medical research company's stock valued at $8,180,000 after buying an additional 17,240 shares during the period. Institutional investors and hedge funds own 88.06% of the company's stock.

Quest Diagnostics Stock Performance

DGX traded down $0.21 during mid-day trading on Thursday, reaching $178.02. 156,382 shares of the company traded hands, compared to its average volume of 959,123. The stock has a market capitalization of $19.87 billion, a P/E ratio of 23.18, a P/E/G ratio of 2.16 and a beta of 0.78. Quest Diagnostics Incorporated has a 52-week low of $135.27 and a 52-week high of $179.37. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82. The company's fifty day moving average price is $169.31 and its 200-day moving average price is $161.59.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.63 billion. On average, sell-side analysts expect that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Insider Activity

In other news, Director Vicky B. Gregg sold 1,250 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $164.57, for a total transaction of $205,712.50. Following the sale, the director now directly owns 16,867 shares in the company, valued at $2,775,802.19. This trade represents a 6.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark E. Delaney sold 403 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $164.30, for a total value of $66,212.90. Following the completion of the sale, the senior vice president now owns 4,624 shares of the company's stock, valued at $759,723.20. The trade was a 8.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,903 shares of company stock valued at $9,460,221 in the last 90 days. Company insiders own 8.16% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. StockNews.com lowered Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Thursday, February 6th. Truist Financial raised their target price on Quest Diagnostics from $182.00 to $190.00 and gave the stock a "hold" rating in a research note on Wednesday, April 23rd. Citigroup downgraded shares of Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 price objective on the stock. in a research report on Tuesday, March 4th. Redburn Partners set a $195.00 target price on Quest Diagnostics in a research report on Wednesday, April 2nd. Finally, Leerink Partnrs raised shares of Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research report on Monday, January 6th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $185.07.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.